Clinical trials
Recurrent clinical trials
Below are recruiting recurrent clinical trials, each written for real people, not researchers. We’re tracking 1,424 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05655312RecruitingPhase 1/Phase 2
Targeted radiation melanoma treatment with or without nivolumab
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
Orange, CaliforniaAges 18–90 - NCT05658081Recruiting
Two surgical stitch methods for Crohn’s bowel surgery
This trial compares two surgical ways of connecting the bowel in people with Crohn’s disease who need bowel resection (removal of a diseased bowel segment) and then reconnect it. If you qualify, the study may help show which method is safer or leads to better recovery.
Nanjing, JiangsuAges 16–60 - NCT05665504Recruiting
Biomarker test for managing early lung nodules after treatment
This study looks at lung “biomarkers” (test results from your nodule/tissue) to better predict risk of cancer coming back and to guide long-term follow-up. It may help doctors choose the best surveillance plan after surgery or other treatment for early, potentially curable lung cancer.
Tampa, FloridaAges 18 years+ - NCT05681780RecruitingPhase 1
CD40L-treated immune cells for advanced lung cancer with certain gene changes
This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.
Tampa, FloridaAges 18 years+ - NCT05682755RecruitingPhase 1/Phase 2
Chidamide to Prevent AML Return After Bone Marrow Transplant
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
Chengdu, SichuanAges 18–65 - NCT05684731RecruitingPhase 1
Test drug KM1 for repeat or resistant ovarian cancer
This early-phase study tests whether KM1 is safe and can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that has come back or not responded to standard treatment. It may help people who have limited options, but eligibility is strict to keep participants safe.
Wuhan, HubeiAges 18 years+ - NCT05701306RecruitingPhase 1
Testing a new medicine for hard-to-treat childhood tumors
This Phase 1 trial tests APG-115 alone or with another drug (APG-2575) in children whose neuroblastoma or other solid tumors have come back or did not respond to treatment. It aims to find a safe dose and see how well the treatment works in these tumors.
Guangzhou, GuangdongAges 12–18 - NCT05701787Recruiting
Study of lung cancer with rare gene changes
This trial looks at the “molecular landscape,” meaning the specific gene changes driving your lung cancer, for people whose non-small cell lung cancer (NSCLC) has rare mutations. The goal is to better understand what those rare changes mean and how they could guide treatment decisions.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05709249RecruitingPhase 3
Chinese herbal medicine to help prevent colon cancer return
This Phase 3 study tests whether a Chinese herbal “decoction” (called XLJDOD) given after surgery and chemo can lower the chance that colon cancer comes back. It may help people with higher-risk colon cancer (Stage IIIB or IIIC) stay cancer-free longer.
NanjingAges 20–80 - NCT05710848RecruitingPhase 1/Phase 2
Study drug for repeat bladder tumor surgery patients
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
Mesa, ArizonaAges 18 years+ - NCT05723926Recruiting
Carotid implants to help prevent stroke repeat in atrial fibrillation
This trial tests whether placing a carotid implant can reduce the chance of having another stroke in people with atrial fibrillation who are already taking blood thinners. It aims to prevent stroke recurrence while you continue prescribed anticoagulation.
Rockford, IllinoisAges 18 years+ - NCT05724719Recruiting
Study brain signals after a first unprovoked seizure
This study looks at people ages 18 to 65 after they have a first seizure that is not clearly triggered. It also compares them with healthy volunteers to better understand what might predict whether seizures come back.
Halifax, Nova ScotiaAges 18–65 - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Phoenix, ArizonaAges 18 years+ - NCT05738980Recruiting
Reduce liver cancer return after surgery using anti–TIM-3
This trial studies whether blocking TIM-3 (an immune “brake”) can help stop hepatocellular carcinoma (liver cancer) from coming back after a curative surgery. It may help by improving your immune system’s ability to find and control remaining cancer cells.
Beijing, Beijing MunicipalityAges 18–75 - NCT05739825Recruiting
Fecal transplant to change gut bacteria in C. difficile infection
This trial studies whether fecal microbiota transplantation (a procedure that transfers healthy stool bacteria) can change a person’s gut bacteria after repeated C. difficile infection. It may help reduce recurring infections by restoring a healthier balance of gut microbes.
RomaAges 18–90 - NCT05753826RecruitingPhase 2
Study of two medicines for platinum-resistant ovarian cancer
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
FujianAges 18–70 - NCT05758610RecruitingPhase 1
Study drug test for relapsed or hard-to-treat AML and NHL
This Phase 1 trial tests ETH-155008, a new medicine, in adults with relapsed or refractory acute myeloid leukemia (AML) or non-Hodgkin lymphoma (NHL). It’s mainly designed to see how the treatment works in the body and whether it may help when standard treatment isn’t available or hasn’t worked.
Zhengzhou, HenanAges 18 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05769660RecruitingPhase 1
Study BEY1107 plus temozolomide for recurrent glioblastoma
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
SeoulAges 19 years+ - NCT05776797Recruiting
Ablation vs best medicines for CRT patients with permanent atrial fibrillation
This trial compares two approaches—an AV junction ablation procedure versus continued best medical treatment—in people who already have a heart device for heart failure (CRT) but still have ongoing permanent atrial fibrillation. It aims to improve how well your heart rhythm is controlled and how effectively the device can pace your heart.
Liberec, Liberec RegionAges 18–85 - NCT05781217RecruitingPhase 3
Short vs longer hormone therapy after salvage prostate radiation
This trial compares two lengths of hormone treatment (androgen deprivation therapy) given around “salvage” radiation after prostate surgery for rising PSA. It aims to see which schedule works best to control prostate cancer while keeping side effects manageable.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT05797831RecruitingPhase 2/Phase 3
Maintenance treatment for TP53-wildtype endometrial cancer
This trial tests navtemadlin as a maintenance (ongoing) treatment to help prevent endometrial cancer from coming back after chemotherapy works. It is mainly for people whose cancer has certain genetic features (TP53 “wildtype”) and who had a strong response to first-line taxane–platinum chemo.
Vallejo, CaliforniaAges 18 years+ - NCT05800405RecruitingEarly Phase 1
Radiation before CAR T therapy for large B-cell lymphoma
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
Duarte, CaliforniaAges 18 years+ - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+
Hear when a new Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent?
- Yes. Clin2 currently lists 1,424 recruiting recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.